Evidence map›Paper›PMID 37653557›Full record

ArticleArthritis research & therapy2023

CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis.

Wessel F Theeuwes, Irene Di Ceglie, Daphne N Dorst, Arjen B Blom, Desiree L Bos, Thomas Vogl, Sander W Tas, Pilar Jimenez-Royo, Mats Bergstrom, Matthew Cleveland and 5 more

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Wessel F Theeuwes *Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Irene Di Ceglie *Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Daphne N DorstDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Arjen B BlomDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Desiree L BosDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Thomas VoglInstitute of Immunology, University of Münster, Münster, Germany.
Sander W TasDepartment of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Centre, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Pilar Jimenez-RoyoResearch and Development, GlaxoSmithKline, Stevenage, UK.
Mats BergstromResearch and Development, GlaxoSmithKline, Stevenage, UK.
Matthew ClevelandBioimaging, In Vitro/In Vivo Translation (IVIVT), GlaxoSmithKline, Stevenage, UK.
Peter M van der KraanDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter LavermanDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Marije I KoendersDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter L van LentDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Martijn H J van den BoschDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands. Martijn.vandenbosch@radboudumc.nl.
Radboud University Nijmegen · NLGlaxoSmithKline (United Kingdom) · GBUniversity of Amsterdam · NLUniversity of Münster · DE

Funding

Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
NIAMS NIH HHS P30 AR070253
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is one of the most prevalent and debilitating joint diseases worldwide. RA is characterized by synovial inflammation (synovitis), which is linked to the development of joint destruction. Magnetic resonance imaging and ultrasonography are widely being used to detect the presence and extent of synovitis. However, these techniques do not reveal the activation status of inflammatory cells such as macrophages that play a crucial role in synovitis and express CD64 (Fc gamma receptor (FcγR)I) which is considered as macrophage activation marker.

objectivesWe aimed to investigate CD64 expression and its correlation with pro-inflammatory cytokines and pro-damaging factors in human-derived RA synovium. Furthermore, we aimed to set up a molecular imaging modality using a radiolabeled CD64-specific antibody as a novel imaging tracer that could be used to determine the extent and phenotype of synovitis using optical and nuclear imaging.

methodsFirst, we investigated CD64 expression in synovium of early- and late-stage RA patients and studied its correlation with the expression of pro-inflammatory and tissue-damaging factors. Next, we conjugated an anti-CD64 antibody with IRDye 800CW and diethylenetriamine penta-acetic acid (DTPA; used for

resultsWe showed that CD64 is expressed in synovium of early and late-stage RA patients and that FCGR1A/CD64 expression is strongly correlated with factors known to be involved in RA progression. Combined, this makes CD64 a useful marker for imaging the extent and phenotype of synovitis. We reported higher binding of the [

conclusionTaken together, we successfully developed an optical and nuclear imaging modality to detect CD64 in human RA synovium in vivo.

Indexed as

Arthritis, RheumatoidSynovitisAnimalsAntibodiesBenzenesulfonatesBiomarkersHumansImmunoglobulin IsotypesIndolesMiceMice, SCIDMolecular ImagingPentetic AcidAntibodiesBenzenesulfonatesBiomarkersImmunoglobulin IsotypesIndolesIRDye 800CWPentetic AcidCD64MacrophageMolecular imagingPreclinical modelsRheumatoid arthritis

Identifiers

PMID37653557
PMCPMC10468866
OpenAlexW4386329046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.